Northern Trust Corp lifted its stake in shares of Cambrex Corporation (NYSE:CBM) by 3.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 566,302 shares of the biotechnology company’s stock after buying an additional 19,955 shares during the period. Northern Trust Corp owned about 1.74% of Cambrex Corporation worth $33,837,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Nisa Investment Advisors LLC boosted its position in shares of Cambrex Corporation by 9.3% during the second quarter. Nisa Investment Advisors LLC now owns 1,760 shares of the biotechnology company’s stock valued at $105,000 after buying an additional 150 shares during the last quarter. Creative Planning boosted its position in shares of Cambrex Corporation by 162.6% during the second quarter. Creative Planning now owns 1,765 shares of the biotechnology company’s stock valued at $105,000 after buying an additional 1,093 shares during the last quarter. Meeder Asset Management Inc. purchased a new position in shares of Cambrex Corporation during the first quarter valued at approximately $109,000. Riverhead Capital Management LLC boosted its position in shares of Cambrex Corporation by 90.3% during the second quarter. Riverhead Capital Management LLC now owns 2,664 shares of the biotechnology company’s stock valued at $159,000 after buying an additional 1,264 shares during the last quarter. Finally, Dubuque Bank & Trust Co. boosted its position in shares of Cambrex Corporation by 3.3% during the second quarter. Dubuque Bank & Trust Co. now owns 2,697 shares of the biotechnology company’s stock valued at $161,000 after buying an additional 87 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/10/16/northern-trust-corp-has-33-84-million-position-in-cambrex-corporation-cbm.html.

Several research analysts recently issued reports on the company. ValuEngine cut Cambrex Corporation from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. BidaskClub cut Cambrex Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, August 24th. Finally, Zacks Investment Research cut Cambrex Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, July 4th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $65.67.

In other Cambrex Corporation news, CEO Steven M. Klosk sold 4,000 shares of Cambrex Corporation stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $54.96, for a total value of $219,840.00. Following the completion of the sale, the chief executive officer now owns 87,328 shares of the company’s stock, valued at approximately $4,799,546.88. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Steven M. Klosk sold 12,000 shares of Cambrex Corporation stock in a transaction on Friday, September 1st. The stock was sold at an average price of $51.53, for a total value of $618,360.00. Following the completion of the sale, the chief executive officer now directly owns 95,328 shares of the company’s stock, valued at approximately $4,912,251.84. The disclosure for this sale can be found here. In the last three months, insiders sold 28,000 shares of company stock valued at $1,574,880. Corporate insiders own 2.48% of the company’s stock.

Cambrex Corporation (CBM) opened at 53.70 on Monday. The firm has a 50-day moving average price of $53.21 and a 200 day moving average price of $55.53. The stock has a market cap of $1.76 billion, a PE ratio of 19.56 and a beta of 2.28. Cambrex Corporation has a 52-week low of $38.30 and a 52-week high of $62.95.

Cambrex Corporation (NYSE:CBM) last posted its earnings results on Friday, August 4th. The biotechnology company reported $0.76 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.76. The business had revenue of $134.55 million during the quarter, compared to analyst estimates of $136.82 million. Cambrex Corporation had a return on equity of 24.25% and a net margin of 17.70%. The company’s quarterly revenue was up 13.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.68 EPS. On average, analysts forecast that Cambrex Corporation will post $3.08 earnings per share for the current fiscal year.

Cambrex Corporation Profile

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Institutional Ownership by Quarter for Cambrex Corporation (NYSE:CBM)

Receive News & Stock Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related stocks with our FREE daily email newsletter.